Skip to main content

Biogen Inc. (BIIB) Stock

Biogen Inc. Stock Details, Movements and Public Alerts

Stock Details

Biogen Inc. (BIIB), a prominent company in the life sciences sector within the biological products, (no disgnostic substances) industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $135.00. Over the past 52 weeks, it has ranged between $110.04 and $236.48. This places the current price at 57.1% of its 52-week high and 22.7% above its 52-week low. Recent trading volume was recorded at 2. The International Securities Identification Number (ISIN) for this stock is US09062X1037.

Market Cap

$18.47B

52-Week High

$236.48

-42.91% from high

52-Week Low

$110.04

+22.68% from low

Avg Daily Volume

2

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

12.46

Below market average

Forward P/E

8.44

Earnings expected to grow

PEG Ratio

6.24

Potentially overvalued

Price to Book

1.09

EV/EBITDA

8.32

EPS (TTM)

$10.12

Price to Sales

1.88

Beta

0.15

Less volatile than market

How is BIIB valued relative to its earnings and growth?
Biogen Inc. trades at a P/E ratio of 12.46, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 8.44 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 6.24 indicates a premium valuation even accounting for growth.
What is BIIB's risk profile compared to the market?
With a beta of 0.15, Biogen Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.09 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

15.10%

Operating Margin

28.10%

Return on Equity

9.19%

Return on Assets

5.43%

Revenue Growth (YoY)

6.10%

Earnings Growth (YoY)

-39.30%

How profitable and efficient is BIIB's business model?
Biogen Inc. achieves a profit margin of 15.10%, meaning it retains $15.10 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 28.10% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 9.19% and ROA at 5.43%, the company achieves moderate returns on invested capital.
What are BIIB's recent growth trends?
Biogen Inc.'s revenue grew by 6.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 39.30% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Company Size & Market

Shares Outstanding

146.53M

Book Value/Share

$115.90

Asset Type

Common Stock

What is BIIB's market capitalization and position?
Biogen Inc. has a market capitalization of $18.47B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 146.53M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.
How does BIIB's price compare to its book value?
Biogen Inc.'s book value per share is $115.90, while the current stock price is $135.00, resulting in a price-to-book (P/B) ratio of 1.16. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$172.20

27.56% upside potential

Analyst Recommendations

Strong Buy

5

Buy

13

Hold

19

Sell

0

Strong Sell

0

How reliable are analyst predictions for BIIB?
37 analysts cover BIIB with 49% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $172.20 implies 27.6% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on BIIB?
Current analyst recommendations:5 Strong Buy, 13 Buy, 19 Hold, 00The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:14 AM

Technical Indicators

What does BIIB's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret BIIB's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for BIIB and get notified when the price changes.

Stay Ahead of the Market with Biogen Inc. Alerts

Set up price alerts for Biogen Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.